Y-mAbs Announces Publication Of Naxitamab-Based Chemoimmunotherapy In Patients With Chemoresistant High-risk Neuroblastoma In The Journal Cancers
Portfolio Pulse from Happy Mohamed
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has announced the publication of a study on naxitamab-based chemoimmunotherapy in patients with chemoresistant high-risk neuroblastoma in the journal Cancers. The study found that early administration of naxitamab-based chemo-immunotherapy significantly improved long-term outcomes. The study's principal investigator suggested that the combination of naxitamab and chemotherapy can overcome chemoresistance when promptly initiated in patients with an incomplete response at the end of induction.
October 16, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The publication of the study on naxitamab-based chemoimmunotherapy could potentially boost the reputation and credibility of Y-mAbs Therapeutics, Inc. This could lead to increased investor confidence and potentially a rise in stock price in the short term.
The publication of a study in a reputable journal often boosts the credibility of a company's products and research. This could lead to increased investor confidence in Y-mAbs Therapeutics, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100